Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Titan für Raketen, Vanadium für Batterien: Radar-Projekt perfekt für die Industrie-Revolution!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4A6 | ISIN: US1717572069 | Ticker-Symbol: 20D0
Frankfurt
12.05.25 | 08:12
16,300 Euro
-1,81 % -0,300
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CIDARA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CIDARA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
17,30017,80012.05.
17,20018,00012.05.

Aktuelle News zur CIDARA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrJMP raises Cidara stock target to $47, maintains outperform2
DoCidara Therapeutics, Inc. - 10-Q, Quarterly Report2
DoCidara Therapeutics, Inc. - 8-K, Current Report1
DoCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results123Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the...
► Artikel lesen
01.05.Cidara Therapeutics Promotes Nicole Davarpanah As Chief Medical Officer-
01.05.Cidara Therapeutics ernennt neuen CMO und SVP3
CIDARA THERAPEUTICS Aktie jetzt für 0€ handeln
01.05.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development143SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics...
► Artikel lesen
29.04.JMP maintains $46 target on Cidara stock ahead of Phase 2b results3
15.04.Cantor Fitzgerald maintains Overweight on Cidara Therapeutics stock3
01.04.Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)83SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®?platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
17.03.Cidara Therapeutics Publishes Preclinical Data On CD388 In Nature Microbiology2
17.03.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology3
12.03.Citizens initiates Cidara with Market Outperform on inlfuenza prevention opportunity2
12.03.Cidara stock gains on JMP analyst's upbeat outlook3
10.03.Cidara stock price target raised to $35 at H.C. Wainwright2
06.03.Cidara Therapeutics GAAP EPS of -$5.37 misses by $1.524
06.03.Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results166Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly...
► Artikel lesen
06.03.Cidara Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
06.03.Cidara Therapeutics, Inc. - 8-K, Current Report-
18.02.Cidara Therapeutics appoints new CFO amid flu drug trials2
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1